Literature DB >> 26363797

IRAS Modulates Opioid Tolerance and Dependence by Regulating μ Opioid Receptor Trafficking.

Fei Li1, Hao Ma1, Ning Wu2, Jin Li3.   

Abstract

Imidazoline receptor antisera-selected (IRAS) protein, the mouse homologue named Nischarin, was found to target to early endosomes with properties of sorting nexins in vitro. Recently, we generated IRAS knockout mice and found IRAS deficiency exacerbated the analgesic tolerance and physical dependence caused by opioids, suggesting that IRAS plays a role in regulating μ opioid receptor (MOR) functions. In the present study, we found that IRAS interacts with MOR and regulates MOR trafficking in vitro. In the CHO or HEK293 cells co-expressing MOR and IRAS, IRAS, through its PX domain, interacted with MOR. The interaction facilitated the recycling of internalized MOR and prevented MOR downregulation induced by DAMGO, the MOR agonist. Functionally, IRAS accelerated MOR resensitization and attenuated DAMGO-induced MOR desensitization, which is believed as one of mechanisms mediating opioid tolerance and dependence. Taken together, we propose that IRAS is a new MOR interacting protein and regulates agonist-induced trafficking of MOR via sorting internalized MOR to the recycling pathway, which may be a molecular mechanism underlying IRAS modulating opioid tolerance and dependence.

Entities:  

Keywords:  Imidazoline receptor antisera-selected protein; Interaction; Receptor trafficking; μ Opioid receptor

Mesh:

Substances:

Year:  2015        PMID: 26363797     DOI: 10.1007/s12035-015-9417-6

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  35 in total

Review 1.  Rab proteins as membrane organizers.

Authors:  M Zerial; H McBride
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

2.  IRAS, a candidate for I1-imidazoline receptor, mediates inhibitory effect of agmatine on cellular morphine dependence.

Authors:  Ning Wu; Rui-Bin Su; Bo Xu; Xin-Qiang Lu; Yin Liu; Jian-Quan Zheng; John E Piletz; Jin Li; Bo-Yi Qin
Journal:  Biochem Pharmacol       Date:  2005-10-01       Impact factor: 5.858

3.  Interaction of the mu-opioid receptor with synaptophysin influences receptor trafficking and signaling.

Authors:  Ying-Jian Liang; Dai-Fei Wu; Li-Quan Yang; Volker Höllt; Thomas Koch
Journal:  Mol Pharmacol       Date:  2006-09-27       Impact factor: 4.436

4.  Generation and primary phenotypes of imidazoline receptor antisera-selected (IRAS) knockout mice.

Authors:  Ling Zhang; Tai-Yun Zhao; Ning Hou; Yan Teng; Xuan Cheng; Bo Wang; Ying Chen; Lei Jiang; Ning Wu; Rui-Bin Su; Xiao Yang; Jin Li
Journal:  CNS Neurosci Ther       Date:  2013-11-04       Impact factor: 5.243

Review 5.  Turning off the signal: mechanisms that attenuate signaling by G protein-coupled receptors.

Authors:  E F Grady; S K Böhm; N W Bunnett
Journal:  Am J Physiol       Date:  1997-09

6.  Imidazoline receptor antisera-selected/Nischarin regulates the effect of agmatine on the development of morphine dependence.

Authors:  Fei Li; Ning Wu; Ruibin Su; Ying Chen; Xinqiang Lu; Yin Liu; Jin Li
Journal:  Addict Biol       Date:  2011-10-04       Impact factor: 4.280

7.  Constitutive activation of the mu opioid receptor by mutation of D3.49(164), but not D3.32(147): D3.49(164) is critical for stabilization of the inactive form of the receptor and for its expression.

Authors:  J Li; P Huang; C Chen; J K de Riel; H Weinstein; L Y Liu-Chen
Journal:  Biochemistry       Date:  2001-10-09       Impact factor: 3.162

Review 8.  Regulated endocytosis of opioid receptors: cellular mechanisms and proposed roles in physiological adaptation to opiate drugs.

Authors:  Mark von Zastrow; Adena Svingos; Helena Haberstock-Debic; Chris Evans
Journal:  Curr Opin Neurobiol       Date:  2003-06       Impact factor: 6.627

Review 9.  The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence.

Authors:  Lene Martini; Jennifer L Whistler
Journal:  Curr Opin Neurobiol       Date:  2007-12-18       Impact factor: 6.627

10.  Generation and characterization of novel human IRAS monoclonal antibodies.

Authors:  Bo Wang; Ying Liu; Yajun Shan; Zhenyu Yao; Xiaolan Liu; Ruibin Su; Qihong Sun; Yuwen Cong; Jin Li
Journal:  J Biomed Biotechnol       Date:  2009-08-10
View more
  5 in total

1.  Modulation of miR-139-5p on chronic morphine-induced, naloxone-precipitated cAMP overshoot in vitro.

Authors:  Dan-Ni Cao; Jing-Jing Shi; Ning Wu; Jin Li
Journal:  Metab Brain Dis       Date:  2018-06-18       Impact factor: 3.584

Review 2.  Role of Nischarin in the pathology of diseases: a special emphasis on breast cancer.

Authors:  Samuel C Okpechi; Hassan Yousefi; Khoa Nguyen; Thomas Cheng; Nikhilesh V Alahari; Bridgette Collins-Burow; Matthew E Burow; Suresh K Alahari
Journal:  Oncogene       Date:  2022-01-22       Impact factor: 9.867

3.  The non-adrenergic imidazoline-1 receptor protein nischarin is a key regulator of astrocyte glutamate uptake.

Authors:  Swati Gupta; Narges Bazargani; James Drew; Jack H Howden; Souvik Modi; Sana Al Awabdh; Hélène Marie; David Attwell; Josef T Kittler
Journal:  iScience       Date:  2022-03-21

4.  Clinical opioids differentially induce co-internalization of μ- and δ-opioid receptors.

Authors:  Fenghua Bao; Chang-Lin Li; Xu-Qiao Chen; Ying-Jin Lu; Lan Bao; Xu Zhang
Journal:  Mol Pain       Date:  2018-03-27       Impact factor: 3.395

5.  Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level.

Authors:  Ronald B Moss; Meghan McCabe Pryor; Rebecca Baillie; Katherine Kudrycki; Christina Friedrich; Mike Reed; Dennis J Carlo
Journal:  PLoS One       Date:  2020-06-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.